1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) First ROXUS® Prescriptions Fulfilled in the United States 06 October 2026 Highlights • First patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s...
First ROXUS Prescriptions Fulfilled in the United States
Filed with ASX · · 3 pages · English
Summary by 6ix AI
LTR Pharma Limited reports the fulfillment of the first patient-specific ROXUS prescriptions in the United States through a telehealth platform, Mavrox, and Strive Pharmacy's support for compounding and fulfillment. This milestone marks the beginning of ROXUS prescription activity under the agreements established with Shed and Strive Pharmacy. The company plans to continue supporting its U.S. partners as prescription activity increases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Earlier from LTR Pharma
- Clinical and Commercial Update - Investor Webinar
- SPONTAN Phase II Final Results
- Notice of Annual General Meeting/Proxy Form
- Application for quotation of securities - LTP
- Investor Presentation
Later from LTR Pharma
- Investor Webinar Presentation
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- SPONTAN passes 2,000 dispensed units in Australia
- SPONTAN to be Evaluated in Pulmonary Arterial Hypertension
- AGM Presentation
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma